DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $35.3750.

Several brokerages have recently weighed in on DBVT. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Guggenheim reaffirmed a “buy” rating and issued a $51.00 target price (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Finally, HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research report on Thursday, December 18th.

Insider Activity

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the transaction, the insider owned 7,303,369 shares in the company, valued at $30,601,116.11. This trade represents a 15.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.44% of the stock is currently owned by company insiders.

Institutional Trading of DBV Technologies

A number of large investors have recently bought and sold shares of the business. New York State Common Retirement Fund purchased a new position in DBV Technologies during the 3rd quarter worth $34,000. GAMMA Investing LLC grew its holdings in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares during the last quarter. Two Sigma Investments LP acquired a new position in DBV Technologies in the 3rd quarter valued at about $167,000. Citadel Advisors LLC acquired a new position in DBV Technologies in the 3rd quarter valued at about $220,000. Finally, DLD Asset Management LP purchased a new stake in DBV Technologies during the 3rd quarter valued at approximately $250,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Price Performance

DBV Technologies stock opened at $20.78 on Tuesday. The stock has a market cap of $834.52 million, a PE ratio of -4.02 and a beta of -1.17. The stock’s fifty day moving average is $16.81 and its two-hundred day moving average is $13.25. DBV Technologies has a 1-year low of $3.80 and a 1-year high of $26.18.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.